home / stock / cmrx / cmrx quote
Last: | $0.943 |
---|---|
Change Percent: | -1.15% |
Open: | $0.9584 |
Close: | $0.943 |
High: | $0.98 |
Low: | $0.93 |
Volume: | 177,453 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.943 | $0.9584 | $0.943 | $0.98 | $0.93 | 177,453 | 07-17-2024 |
$0.9475 | $0.94 | $0.9475 | $0.9845 | $0.9171 | 524,534 | 07-16-2024 |
$0.9357 | $0.909 | $0.9357 | $0.9391 | $0.8951 | 279,850 | 07-15-2024 |
$0.8985 | $0.8998 | $0.8985 | $0.9091 | $0.8735 | 182,323 | 07-12-2024 |
$0.883 | $0.8211 | $0.883 | $0.8993 | $0.8211 | 289,859 | 07-11-2024 |
$0.8386 | $0.81 | $0.8386 | $0.8458 | $0.81 | 254,033 | 07-10-2024 |
$0.8204 | $0.81 | $0.8204 | $0.8322 | $0.7942 | 181,868 | 07-09-2024 |
$0.8175 | $0.83 | $0.8175 | $0.83 | $0.78 | 399,044 | 07-08-2024 |
$0.835 | $0.8775 | $0.835 | $0.8775 | $0.815 | 362,048 | 07-05-2024 |
$0.8695 | $0.87 | $0.8695 | $0.8774 | $0.86 | 56,216 | 07-04-2024 |
$0.8695 | $0.87 | $0.8695 | $0.8774 | $0.86 | 56,216 | 07-03-2024 |
$0.8625 | $0.8699 | $0.8625 | $0.8895 | $0.86 | 244,393 | 07-02-2024 |
$0.869 | $0.8889 | $0.869 | $0.8995 | $0.867 | 216,679 | 07-01-2024 |
$0.876 | $0.8885 | $0.876 | $0.8998 | $0.875 | 268,362 | 06-28-2024 |
$0.8891 | $0.8829 | $0.8891 | $0.8999 | $0.881 | 116,861 | 06-27-2024 |
$0.883 | $0.92 | $0.883 | $0.9251 | $0.882 | 327,370 | 06-26-2024 |
$0.9251 | $0.9138 | $0.9251 | $0.9285 | $0.8849 | 248,298 | 06-25-2024 |
$0.9065 | $0.8886 | $0.9065 | $0.9135 | $0.88 | 141,701 | 06-24-2024 |
$0.89 | $0.876 | $0.89 | $0.8984 | $0.876 | 131,636 | 06-21-2024 |
$0.89 | $0.88 | $0.89 | $0.9097 | $0.8725 | 163,402 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data...